GI Innovation (358570.KQ) Stock Price

GI Innovation Price

CLOSED
6,750.00
​
Market closed

Revenue at GI Innovation has contracted by 11.9% per year over the past 5 years to 5.84 B KRW. GI Innovation's net margin stands at -601.8%, up from -2,691.8% several years earlier. Analysts set a median price target of 25,500.00 KRW, implying 277.8% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

GI Innovation stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GI Innovation business model & stock analysis

GI Innovation Inc is a biotechnology firm headquartered in Seoul, South Korea, operating within the health care sector. The company was established to focus on the research and development of innovative biopharmaceutical products, aiming to address significant unmet medical needs through advanced scientific approaches. As a relatively young entity in the industry, GI Innovation went public on March 30, 2023, marking a significant milestone in its corporate development and providing it with the necessary capital to accelerate its pipeline activities. The organization currently employs a team of 84 full-time professionals who are dedicated to advancing its drug discovery and development programs. The business model of GI Innovation is distinct in that it primarily generates revenue through license fees derived from the technology transfer of its proprietary drug candidates. This strategy allows the company to monetize its intellectual property and research findings without necessarily bearing the full cost and risk of late-stage clinical trials and commercialization for every asset. The core of the company's value proposition lies in its pipeline of new drug candidates that are currently in pre-clinical and early clinical stages. Among its most notable assets are GI-101, an immuno-oncology therapy designed to harness the body's immune system to fight cancer, and GI-301, a treatment aimed at addressing allergic conditions. These candidates represent the company's strategic focus on high-potential therapeutic areas where novel mechanisms of action can provide competitive advantages. By leveraging its expertise in biopharmaceutical development, GI Innovation seeks to establish itself as a meaningful player in the global biotechnology landscape. The company's website, https://www.gi-innovation.com/, serves as a primary resource for stakeholders seeking further information on its scientific progress and corporate updates. With its recent IPO and a focused pipeline, GI Innovation Inc is positioned to navigate the complexities of drug development while aiming to deliver impactful healthcare solutions to patients worldwide. The company's ISIN, KR7358570000, and ticker symbol, 358570.KQ, facilitate its trading on the Korean market, allowing investors to participate in its growth trajectory.

Frequently asked questions about GI Innovation

Analysts currently set an average price target of 25,500.00 KRW for the GI Innovation stock (median: 25,500.00 KRW), implying +277.8 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the GI Innovation stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect GI Innovation to generate revenue of 63.63 B KRW and earnings per share of -649.03 KRW.

Converted at the current exchange rate, the GI Innovation share trades at 4.59 EUR (6,750.00 KRW).

The expected revenue of GI Innovation is 63.63 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of GI Innovation is -41.45 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of GI Innovation is currently -10.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the GI Innovation stock.

The price-to-sales ratio (P/S) of GI Innovation is currently 6.77. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the GI Innovation stock.

The Eulerpool Quality Score for GI Innovation is 4/10.

The ISIN of GI Innovation is KR7358570000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of GI Innovation is 358570.KQ. The ticker symbol is used to trade GI Innovation shares on the stock exchange.

Fair ValueTerminal
5,535.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
69.50 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Mar 30, 2023
ISIN
KR7358570000
Cusip
Y270CB104
Market capitalization
352.44 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-10.40
P/Se
6.77
EV/EBIT
—
P/B Ratio
3.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-30.16 %
Last updated Nov 22, 2026, 3:41 AM

GI Innovation Peer Group

GI Innovation FIGI

358570:KS · BBG00LB7KLW1358570:KQ · BBG01DMQZX61

All fundamentals and in-depth analysis of GI Innovation

Our stock analysis for GI Innovation stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GI Innovation. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.